Short Term Rating on Array BioPharma (ARRY)

Array BioPharma (ARRY) : Zacks Investment Research ranks Array BioPharma (ARRY) as 2, which is a Buy recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 8 research analysts is 1, which indicates as a Strong Buy.

Array BioPharma (ARRY) has been rated by 6 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $13 and the lowest price target forecast is $7. The average forecast of all the analysts is $8.5 and the expected standard deviation is $2.35.

For the current week, the company shares have a recommendation consensus of Buy.


Array BioPharma (NASDAQ:ARRY): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $3.79 and $3.73 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $3.83. The buying momentum continued till the end and the stock did not give up its gains. It closed at $3.78, notching a gain of 1.07% for the day. The total traded volume was 1,436,398 . The stock had closed at $3.74 on the previous day.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *